Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsXTER:01P -1.06%96 3-Year EBITDA Growth Rate is 28.70% as of Jun. 2026, which is 36% above its 10-year median of 21.10. GuruFocus rates XTER:01P with a GF Score™ of 96/100 and a GF Value™ of €462.90 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 72.12% on this metric.
During the past 12 months, Medpace Holdings's average EBITDA Per Share Growth Rate was 29.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 28.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 32.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 24.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medpace Holdings was 36.60% per year. The lowest was 6.20% per year. And the median was 21.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medpace Holdings 3-Year EBITDA Growth Rate Related Terms
XTER:01P vs : 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 28.70% mean?
Medpace Holdings (XTER:01P) has a 3-Year EBITDA Growth Rate of 28.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medpace Holdings and its competitors. This is 36% above median its historical median of 21.10. Over the past decade, Medpace Holdings' 3-Year EBITDA Growth Rate has ranged from 6.20 to 36.60. According to the industry distribution chart, Medpace Holdings ranks #46 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 27.9%.
Is Medpace Holdings' 3-Year EBITDA Growth Rate too high?
Medpace Holdings' current 3-Year EBITDA Growth Rate of 28.70% is 36% above median its 10-year median of 21.10. Over the past 10 years, this metric has ranged from a low of 6.20 to a high of 36.60. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. Medpace Holdings' value of 28.70% is 160.9% above this industry median. Based on the distribution chart, Medpace Holdings ranks #46 out of 165 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Medpace Holdings has a GF Score™ of 96/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' 3-Year EBITDA Growth Rate compare to ?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #46 out of 165 companies for 3-Year EBITDA Growth Rate. This puts Medpace Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. Medpace Holdings' value of 28.70% is 160.9% above this benchmark. Historically, Medpace Holdings' own 3-Year EBITDA Growth Rate has ranged from 6.20 to 36.60 over the past decade. While the company's 10-year median is 21.10 vs. the industry median of 11.00, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current 3-Year EBITDA Growth Rate of 28.70% is 160.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current 3-Year EBITDA Growth Rate is 28.70%, which is 36% above median its own 10-year median of 21.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (XTER:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €462.90, compared to a current price of €524.00 — trading 13.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 28.70%, which is 36% above median its 10-year median of 21.10 and 160.9% above the Medical Diagnostics & Research industry median of 11.00. Medpace Holdings' overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medpace Holdings (XTER:01P), the current 3-Year EBITDA Growth Rate is 28.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (XTER:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €524.00 is trading 13.2% above its estimated GF Value™ of €462.90.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for XTER:01P:
3-Year EBITDA Growth Rate: 28.70% (36% above median its 10-year median of 21.10)
GF Value™: €462.90 vs. price of €524.00 (13.2% above fair value)
Industry Position: 160.9% above the Medical Diagnostics & Research median (#46 of 165)
No single metric tells the full story. See the XTER:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
96GF Score
Get the complete analysis for XTER:01P
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:01P has been successfully added to your 
